UCB (OTCMKTS:UCBJY) Shares Gap Down – Here’s Why

UCB SA (OTCMKTS:UCBJY) shares gapped down before the market opened on Monday . The stock had previously closed at $158.72, but opened at $150.53. UCB shares last traded at $151.3950, with a volume of 26,509 shares.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Wolfe Research raised shares of UCB to a “strong-buy” rating in a research note on Monday, February 23rd. Zacks Research downgraded shares of UCB from a “hold” rating to a “strong sell” rating in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy”.

UCB Stock Down 5.0%

The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38. The business’s 50 day moving average is $145.77 and its two-hundred day moving average is $147.25.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.